PS240 Clinical and Hemodynamic Analysis of the Treatment With Ivabradine in Severe Aortic Stenosis

Quiroga, Gustavo Aníbal Cortez; Mansilla, Carmen Rus; Torralba, M.C. Durán; Lucas, L.; Grasiosi, Jorge Curotto; Moyano, M.G. Lopéz; Andrès, Emmanuel; Casado, Cuesta; Floro, A. Sanchez; Llavero, L. Martinez

doi:10.1016/j.gheart.2016.03.188

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five studies have evaluated the use of ivabradine in patients with severe AS (Table 3). 53–57 Although no differences were noted in HR reduction, one study found ivabradine was associated with an increased LVEF compared to baseline therapy with β‐blockers 53 . Three studies found ivabradine decreased HR; two of these observed improvements in both LVEF and exercise tolerance 54–56 .…”

Section: Resultsmentioning

confidence: 99%

“… 53–57 Although no differences were noted in HR reduction, one study found ivabradine was associated with an increased LVEF compared to baseline therapy with β‐blockers 53 . Three studies found ivabradine decreased HR; two of these observed improvements in both LVEF and exercise tolerance 54–56 . In a study of 98 patients with severe AS, sinus rhythm, and preserved ejection fraction who were followed for 2.6 years, ivabradine was associated with a significantly lower risk of death from any cause, hospitalization, or the composite compared to standard care (e.g., β‐blockers) 57 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults

2020

View full text Add to dashboard Cite

Ivabradine lowers heart rate by inhibiting the hyperpolarization-activated current in pacemaker cells, and its use for the treatment of heart failure (HF) and ischemic heart disease (IHD) is well described. Ivabradine may be an attractive treatment option for other conditions for which a reduction in heart rate is desirable but less is known about its role in these settings. The primary objective was to perform a scoping review summarizing the literature evaluating novel uses for ivabradine other than HF and IHD in adults. PubMed and EMBASE were searched for articles for all dates through September 2019. Search strategies combined terms generic, commercial/trade, and international names for ivabradine. Manual search of references was also performed to identify additional articles. Studies were included if they were published in English, evaluated the efficacy of ivabradine for indications other than HF or IHD in patients aged 18 years or older, and the primary outcome included clinically relevant end points. Articles were screened first by title and abstract followed by full-text screening of the remaining articles. After removal of duplicates, 1807 records were screened for inclusion and 84 studies were included in this scoping review. Novel uses of ivabradine were reported for various tachyarrhythmias, valvular heart disease, premedication for coronary computed tomography angiography, perioperative risk reduction, sepsis with and without multi-organ dysfunction syndrome, cor pulmonale, reactive airway disease, and erectile dysfunction. This scoping review identified several potential novel uses for ivabradine in adults. This review may help to identify existing gaps where further research is needed to elucidate the role of ivabradine for indications beyond HF and IHD. KEY WORDS ivabradine, tachycardia, asthma, CT angiography, perioperative risk reduction, pulmonary hypertension, multi-organ dysfunction syndrome, valvular heart disease.

show abstract

Section: Resultsmentioning

confidence: 99%